Cardiomyopathy

Landmark approval announced for life-saving heart condition treatment

Patients with a rare heart condition are set to benefit from a landmark approval for a new drug that can significantly reduce risk of both hospitalisation and death, NHS England (NHSE) has announced.

The treatment, known as tafamidis, is the first ever approved treatment for a cohort of patients in England with transthyretin amyloidosis cardiomyopathy (ATTR-CM), which sees clumps of protein build up in the heart, risking heart failure and mortality.

The news comes after the National Institute for Health and Care Excellence gave the treatment the green light in final draft guidance.

Final guidance is expected next month, but tafamidis will be available immediately to NHS patients through the Innovative Medicines Fund, until routine availability is confirmed.

Clinical trials showed that the treatment – which is sold by Pfizer under the name, Vyndaqel – reduced the risk of death in patients by 41% compared to a placebo, with fewer hospitalisations also observed.

The Scottish Medicines Consortium accepted the drug for use within NHS Scotland on adult ATTR-CM patients in November 2023. In England, approximately 1,500 have been diagnosed with ATTR-CM.

Andrew Stephenson comment

”A first of its kind, tafamidis will give those living with this rare progressive condition new hope,” said NHSE’s national clinical director for heart disease, Professor Simon Ray.

He added: “This pioneering drug is just one example of the NHS delivering on its commitment to ensure patients across the country have access to the latest and most effective treatments to help significantly improve their quality of life.”

Tafamidis works by slowing the build-up of dangerous protein deposits and is taken once a day as a capsule.

Previous treatment options in this area have been limited and primarily focused on symptom management and supportive care.

Joel Rose, CEO at Cardiomyopathy UK, explained: “ATTR-CM has significant impacts on an individual’s everyday life and we are really pleased there is now a treatment option which could help improve their care.

“We now must make sure that this treatment can get to those who will benefit as quickly as possible as ATTR-CM often worsens over time.”

To learn more about the latest innovations coming from clinical trials and the pharmaceutical industry, register for National Health Executive’s life sciences online conference later this year.

Image credit: iStock

Website cover

NHE May/June 2024

Join the conversation shaping the future of healthcare.

Click below to read more!

More articles...

View all
Online Conference

Presenting

2024 Online Conferences

In partnership with our community of health sector leaders responsible for delivering the UK's health strategy across the NHS and the wider health sector, we’ve devised a collaborative calendar of conferences and events for industry leaders to listen, learn and collaborate through engaging and immersive conversation. 

All our conferences are CPD accredited, which means you can gain points to advance your career by attending our online conferences. Also, the contents are available on demand so you can re-watch at your convenience.

National Health Executive Podcast

Listen to industry leaders on everything within healthcare

Whether it's the latest advancements in medical technology, healthcare policies, patient care innovations, or the challenges facing healthcare providers, we cover it all.

 

Join us as we engage with top healthcare professionals, industry leaders, and policy experts to bring you insightful conversations that matter.